The Supreme Court has directed the Union and the Delhi governments to ensure that from the next academic year, an MBBS aspirant seeking admission in a medical college on a Nominees of Government of India (NGOI) category seat takes the all-India entrance test to secure it.
A candidate under the NGOI category is one who belongs to a state or Union territory where there are no adequate medical colleges. They also include the children of the Defence or the paramilitary force personnel, who have sacrificed their lives or have been permanently disabled in wars or terrorist attacks.
A bench of justices A K Patnaik and Swatanter Kumar also held that no student under the NGOI category, who has failed the Delhi University Medical Entrance Test (DUMET), would be granted admission to a medical college here.
“We direct that from the academic year 2013-2014 onwards, the candidate applying for the seats reserved for NGOI have to obtain the minimum prescribed mark in the All India National Eligibility-cum-Entrance Test for admission to the MBBS course as provided in the amended MCI Regulations and the admissions will be made on merit…”
“We direct that with effect from academic year 2012-2013, no admission will be made to any of the seats reserved for NGOI in Lady Hardinge Medical College (LHMC), Maulana Azad Medical College (MAMC) and University College of Medical Sciences (UCMS) of any student who has failed in the Delhi University Medical Entrance Test (DUMET),” the bench said.
The apex court’s directions came on appeals filed by two MBBS aspirants against the Delhi High Court’s verdict, which had dismissed their plea challenging the NGOI category and the practice of exempting students under this category from taking the DUMET.
DigitalLEARNING, is an initiative of Elets Techomedia Pvt Ltd existing since 2003. Now, Elets' YouTube channel -- Elets tv, a treasure of premier innovation-oriented knowledge-conferences and awards, is also active.
To Subscribe Free, Click Here
Like us on Facebook, connect with us on LinkedIn and follow us on Twitter.